About this Research Topic
The microbiome, which refers to the community of microorganisms that inhabit the human body, particularly the gut, plays a significant role in the development and progression of inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. In individuals with IBD, there is often a disruption of the microbiome balance, a condition known as dysbiosis. Dysbiosis in IBD patients can lead to inappropriate immune responses, including chronic inflammation. Dysbiosis is characterized by alterations in the composition and function of the gut microbiota, including decreases in microbial diversity and shifts in the abundance of certain bacterial species. Certain bacteria may trigger an immune response, leading to inflammation and tissue damage in the gut.
1- Advancing scientific understanding: The primary goal is to contribute to the advancement of knowledge in the field of IBD and the microbiome, to provide insights into the complex interactions between the gut microbiome and IBD pathogenesis, progression, and treatment.
2-Identifying biomarkers: Another goal is to identify potential biomarkers associated with IBD and the microbiome. This could involve research into specific microbial signatures or host factors that could be used for diagnostic, prognostic, or therapeutic purposes.
3-Exploring therapeutic interventions: to explore novel therapeutic interventions targeting the gut microbiome in IBD. This could include research into probiotics, prebiotics, fecal microbiota transplantation (FMT), dietary interventions, and microbiome-modulating drugs.
The scope of the Research Topic encompasses a broad range of themes aimed at advancing our understanding of the complex interplay between the gut microbiome and IBD pathogenesis, progression, and treatment. These are the specific themes that contributors could address:
1- Microbial dysbiosis in IBD: Investigate alterations in the composition, diversity, and function of the gut microbiota in individuals with IBD compared to healthy controls. Explore how dysbiosis contributes to IBD development, severity, and clinical outcomes.
2- Host-microbiome interactions: Explore the mechanisms underlying interactions between the gut microbiome and the host immune system, mucosal barrier function, and metabolic processes in the context of IBD. Investigate how these interactions influence disease pathogenesis and progression.
3- Microbial biomarkers: Identify microbial biomarkers associated with IBD diagnosis, prognosis, and treatment response. Investigate the utility of microbial signatures, microbial metabolites, and host-microbiome interactions as diagnostic and prognostic markers for IBD.
4- Therapeutic interventions: Evaluate the efficacy and safety of therapeutic interventions targeting the gut microbiome in IBD, including probiotics, prebiotics, synbiotics, fecal microbiota transplantation (FMT), dietary interventions, antibiotics, and microbiome-modulating drugs. Investigate mechanisms of action and factors influencing treatment response.
1- Advancing scientific understanding: The primary goal is to contribute to the advancement of knowledge in the field of IBD and the microbiome, to provide insights into the complex interactions between the gut microbiome and IBD pathogenesis, progression, and treatment.
2-Identifying biomarkers: Another goal is to identify potential biomarkers associated with IBD and the microbiome. This could involve research into specific microbial signatures or host factors that could be used for diagnostic, prognostic, or therapeutic purposes.
3-Exploring therapeutic interventions: to explore novel therapeutic interventions targeting the gut microbiome in IBD. This could include research into probiotics, prebiotics, fecal microbiota transplantation (FMT), dietary interventions, and microbiome-modulating drugs.
The scope of the Research Topic encompasses a broad range of themes aimed at advancing our understanding of the complex interplay between the gut microbiome and IBD pathogenesis, progression, and treatment. These are the specific themes that contributors could address:
1- Microbial dysbiosis in IBD: Investigate alterations in the composition, diversity, and function of the gut microbiota in individuals with IBD compared to healthy controls. Explore how dysbiosis contributes to IBD development, severity, and clinical outcomes.
2- Host-microbiome interactions: Explore the mechanisms underlying interactions between the gut microbiome and the host immune system, mucosal barrier function, and metabolic processes in the context of IBD. Investigate how these interactions influence disease pathogenesis and progression.
3- Microbial biomarkers: Identify microbial biomarkers associated with IBD diagnosis, prognosis, and treatment response. Investigate the utility of microbial signatures, microbial metabolites, and host-microbiome interactions as diagnostic and prognostic markers for IBD.
4- Therapeutic interventions: Evaluate the efficacy and safety of therapeutic interventions targeting the gut microbiome in IBD, including probiotics, prebiotics, synbiotics, fecal microbiota transplantation (FMT), dietary interventions, antibiotics, and microbiome-modulating drugs. Investigate mechanisms of action and factors influencing treatment response.
Keywords: Microbiome, inflammatory bowel diseases, gut, Microbiota, Crohn's disease, Ulcerative colitis
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
